Annual report pursuant to Section 13 and 15(d)

CONSOLIDATED STATEMENTS OF OPERATIONS

v3.20.1
CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2019
Dec. 31, 2018
COSTS AND EXPENSES:    
Research and development $ 18,192 $ 17,558
General and administrative 10,636 8,764
Total costs and expenses 28,828 26,322
Operating Loss (28,828) (26,322)
Interest income, net 210 233
Net loss (28,618) (26,089)
Preferred stock deemed dividend 2,474 3,266
Net loss available to common stockholders $ (31,092) $ (29,355)
Net loss per common share, basic and diluted (in dollars per share) $ (19.33) $ (259.85)
Weighted average common shares outstanding, basic and diluted (in shares) 1,608,568 112,968